Analyst: Bavarian Nordic continues hot streak
A run of very good news for the Danish vaccine maker, including winning the European monkeypox authorization as the infection is declared a global threat, is evident on a skyrocketing stock price.
by marketwire, translated by daniel pedersen
On Monday, the EU Commission authorized Bavarian Nordic to broaden its vaccine label for smallpox vaccine Imvanex, adding monkeypox. This followed hot on the heels of the European Medicines Agency’s approval recommendation on Friday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
WHO declares monkeypox global health emergency
For subscribers
Needham lifts Bavarian Nordic's target stock price 13%
For subscribers
